To our knowledge, this is the first demonstration that combination of a CDK2/9 inhibitor and a BCL2 family inhibitor is beneficial in human colorectal cancer cell lines and may support widening the scope of indications in which these agents are tested. This evidence concerns the gene CDK2 and colorectal cancer.